Will The $3bn Stimulus Amid COVID-19 Place Indian Cos Among Goliaths?
INR 51bn Investments Committed Under First PLI Scheme
Executive Summary
Following an INR69bn incentive scheme for APIs, the Indian government has come up with an INR150bn scheme for formulations and more. Will this $3bn push prove to be the one that companies like Sun Pharma and Aurobindo, currently at 36 and 48 respectively in Scrip 100 rankings, need to break into the top league?
You may also be interested in...
Hot Space: PE Advent Snaps Up Second API Manufacturer In India
Private equity investor Advent has acquired API maker ZCL Chemicals in India, its second transaction in a segment seeing rising interest as pharma de-risks sourcing for key ingredients post COVID-19-related turbulence.
Webinar Recording: India Supply Chain Issues Against The Backdrop Of COVID-19
Join Anju Ghangurde and Vibha Ravi in this recorded session from Informa Pharma Intelligence's recent 24-hour webinar series on COVID-19: Lessons Learned And A Path Forward.
India’s Bulk Drugs Incentive Scheme Finds Takers In Mankind, Aarti
As India revealed finer details of two schemes to promote bulk drug production, Mankind Pharma and Aarti Drugs spelled out a preference for chemical synthesis products - they are likely to be joined by more companies reluctant to invest in some that are fermentation-based. Whether a “plug and play” format for bulk drug parks will attract foreign investment remains to be seen.